AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04366089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxychloroquine
Description: dose: 200 mg, 1 cp x 2 / day
Study NCT02429206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SQIN
Description: Each patient will be asked to self-apply both creams (experimental vs positive control) on the right and left sides of their body (sides will be randomly assigned).
Study NCT02429206 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard moisturizing cream (Glaxal Base)
Study NCT03686527 — intervention group
Intervention type: PROCEDURE
Intervention: stenosis aortic valve
Description: The exams to be realized :~* a clinical examination with blood pressure~* a 12-lead surface electrocardiogram~* a standard biological assessment including NTproBNP (Brain Natriuretic Peptide)~* Transthoracic echocardiography at baseline and 12 months after the aortic valve intervention on the (according to recommendations)~* a cardiac MRI looking for fibrosis myocardial
Study NCT00716040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social-psycho intervention to improve adherence to HAART
Description: The intervention focus on the notion of scenes and scenarios to examine and discussing the experience of taking ARV medicines. In principle, such an approach provides a tool for conscientization, action and the invention of novel group and individual repertoires that may result in individual mobilization for improving adherence to treatment and reducing his/her vulnerability.
Study NCT00716040 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: The control group will be submitted to the usual care of the health service
Study NCT01945190 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Study NCT02871570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivipansel
Description: A single dose of IV Rivipansel over 20 minutes
Study NCT03491475 — intervention group
Intervention type: DRUG
Intervention: Ajmaline test
Description: Administration of Ajmaline
Study NCT04838340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standart care
Description: This group will leave in the hospital's usual care and no intervention will be applied.
Study NCT04838340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnobirthig training
Description: Hypnobirthing training of the Hypnobirthing group will carry out with its partner. Hypnobirthig training will be given in small groups of 5 or 6 couples for 4 weeks and 3 hours a week. In addition, the usual care will be provided by healthcare professionals to this group.~Breathing, relaxation exercises, birth stories and birth videos will be used to reduce fears of chlildbirt women.~Deepening and endorphin massage techniques will be given for labor pain. After the endorphin massage technique will be applied individually by the researcher, it will be applied by the couples and they will ask for repeating all exercises at home.~In the last week of the training, there will be a birth rehearsal with Hynobirthing methods with the partners.~The second meeting will take place when labor begins and after labor.
Study NCT03500536 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IntelliCare
Description: A suite of mobile apps that use principles of computerized therapy to decrease symptoms of depression.
Study NCT03013426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVX-508
Description: Administration of NVX-508 emulsion intravenously
Study NCT02292524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Commercially-available tomato food product
Description: Each of the three tomato food products (juice, soup, sauce) provided 25-35 mg lycopene/day.
Study NCT03387826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel 5mg
Description: Prasugrel 5 mg once daily
Study NCT03387826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel 5mg
Description: Prasugrel 5 mg once daily
Study NCT00880828 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative cervical collar with Acetaminophen
Description: Conservative cervical collar with Acetaminophen QID/PRN for 4 weeks
Study NCT00880828 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen only
Description: Acetaminophen QID/PRN for 4 weeks
Study NCT00813735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: Eszopiclone 2mg daily at bedtime
Study NCT00813735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily at bedtime
Study NCT00813735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram 10mg or 20mg
Study NCT00813735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram 10mg or 20mg
Study NCT01841983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Be Well Work Well
Description: The intervention follows principles for integrated approaches to promoting and protecting worker health. It will occur on 4 inpatient units at Massachusetts General Hospital beginning in January 2013, and will continue for 1 year.~Overall intervention objectives:~1. Motivate individual staff members to engage in targeted health and safety behavior changes;~2. build awareness of ergonomic and safety hazards and of opportunities for healthy dietary choices and physical activity;~3. facilitate unit-level norms supportive of breaks, safe patient handling, and targeted health and safety behaviors; and~4. promote co-worker and supervisor support for targeted health and safety behaviors.
Study NCT01025752 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face to face cognitive behavior therapy
Description: Ten session face to face cognitive behavior therapy for chronic low back pain
Study NCT01025752 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IVR based cognitive behavioral therapy
Description: Ten session cognitive behavior therapy for chronic low back pain using interactive voice response therapy
Study NCT03067168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 5 mL of 0.5% bupivacaine will be injected into 2 locations bilaterally.
Study NCT03067168 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline 0.9%
Description: 5 mL of 0.9% normal saline will be injected into 2 locations bilaterally.
Study NCT01625702 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CellSearch® CTC kit
Description: Collect peripheral blood sample of 100 gastric cancer patients pre-chemotherapy treated with capecitabine/paclitaxel (XPa) and capecitabine/cisplatin (XP) and post two cycles of chemotherapy(response evaluation).~Blood samples will be transferred to central lab to detect CTCs by Cellsearch kit.~Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
Study NCT05283668 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: i-PRF
Description: * Local anesthesia was achieved using field block technique.~* A soft tissue diode surgical laser unit was used in a contact method using a flexible fiber optic hand piece with initiated tip.~* Laser irradiation parameters were adjusted as follows: Wavelength \[940 ± 10 nm\], irradiation mode \[contact continuous wave\], Power \[2 W\] and 300 μm fiber tip diameter (Jokar et al., 2019).~* The treatment was depigmentation by laser thin injection by I-PRF Post-operative instructions Instruct the patients to avoid tooth brushing on the day of surgical treatment to prevent mechanical trauma and allow re-epithelialization.
Study NCT05283668 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diode Laser
Description: Local anesthesia was achieved using field block technique.~* A soft tissue diode surgical laser unit was used in a contact method using a flexible fiber optic hand piece with initiated tip.~* Laser irradiation parameters were adjusted as follows: Wavelength \[940 ± 10 nm\], irradiation mode \[contact continuous wave\], Power \[2 W\] and 300 μm fiber tip diameter (Jokar et al., 2019).~Post-operative instructions Instruct the patients to avoid tooth brushing on the day of surgical treatment to prevent mechanical trauma and allow re-epithelialization.
Study NCT05283668 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diode Laser
Description: Local anesthesia was achieved using field block technique.~* A soft tissue diode surgical laser unit was used in a contact method using a flexible fiber optic hand piece with initiated tip.~* Laser irradiation parameters were adjusted as follows: Wavelength \[940 ± 10 nm\], irradiation mode \[contact continuous wave\], Power \[2 W\] and 300 μm fiber tip diameter (Jokar et al., 2019).~Post-operative instructions Instruct the patients to avoid tooth brushing on the day of surgical treatment to prevent mechanical trauma and allow re-epithelialization.
Study NCT02146898 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Position
Study NCT02066948 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: meal pattern
Description: skew or even
Study NCT02066948 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: even
Description: even amount of protein distributed between each meal
Study NCT02066948 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: skew
Description: a skewed amount of protein is distributed between each meal
Study NCT04913402 — intervention group
Intervention type: OTHER
Intervention: Sufentanil administered by paramedics after the phone call consultation of medical doctor.
Description: Administration of sufentanil to patients with acute injury by paramedics only after phone-call consultation of medical doctor.
Study NCT02817776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERMOCOOL SMARTTOUCH® SF catheter
Description: Radiofrequency Ablation
Study NCT04913402 — intervention group
Intervention type: OTHER
Intervention: Sufentanil administered by paramedics based on their competency, without consultation of medical doctor.
Description: Administration of sufentanil to patients with acute injury by paramedics with competency to administer sufentanil without medical doctor consultation.
Study NCT00709176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief FOCUS Program
Description: Dyads randomized to this arm received the FOCUS Brief Program, two home visits and one phone call by a trained nurse.
Study NCT00709176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extensive FOCUS Program
Description: Dyads randomized to this arm received the FOCUS Extensive Program, 4 home visits and two phone calls by a trained nurse.
Study NCT01895400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Renexin (cilostazol 100mg + gingko biloba extract 80 mg)
Description: Take Renexin 1T bid po medication for 8 weeks
Study NCT01895400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take placebo drug 1T bid po medication for 8 weeks
Study NCT04435301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DC-Stimulator, NeuroConn, Germany
Description: Neurostimulation device
Study NCT04435301 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DC-Stimulator, NeuroConn, Germany
Description: Neurostimulation device
Study NCT01903772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Study NCT00023764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT03550898 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Dynamic Ultrasonography
Description: Dynamic Ultrasonography was performed with patients in supine position, with a suprapubic sagittal position transductor, during filling phase of urodynamics.
Study NCT01464099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: An initial priming dose of insulin aspart is administered, then a continuous subcutaneous insulin aspart infusion followed by a bolus of insulin aspart on top of the continuous insulin aspart infusion
Study NCT01903772 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Inspiratory Muscle Training
Study NCT02759601 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tefinostat
Description: Tefinostat is a novel type of HDACi used in cancer targeted specifically to cell of monocyte - macrophase lineage
Study NCT04800549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Mucositis
Description: The data of the study were obtained by conducting six interviews with each child and the family. The first interview was conducted before starting to treatment on the first day of the treatment, the second interview was conducted on the 2nd day after the treatment and the following interviews were conducted on the 4th, 8th, 16th, and 21st days and in-mouth mucosa of the patient was evaluated by taking in-mouth pictures following interviewing with the child and the family. Oral care application was conducted four times a day with sodium bicarbonate solution and a lollipop made with black mulberry syrup (after meals and before going to the bed at night). Oral care was first conducted by the researcher, the oral care was then taught to the patient and patient's relatives and the application was evaluated. Figure 1 shows the study design.
Study NCT02951975 — intervention group
Intervention type: DRUG
Intervention: dexamethasone intravitreal implant
Description: Dexamethasone intravitreal implant (OZURDEX®) as prescribed in clinical practice.
Study NCT02201212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study NCT00400816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Schedule of Temozolomide administration: Temozolomide, 150 mg/m2/d x days 1-7 and 15-21, given every 28 days \[i.e., 7 days on/7 days off\]
Study NCT02475330 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed
Description: Whole grain flaxseed diet consisting of 40g flaxseed ingested per day
Study NCT01410643 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Macronutrient Modification
Description: reduced carbohydrate versus standard carbohydrate diet
Study NCT02091466 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pre-warming
Description: warming patients 30 minutes prior to anesthesia
Study NCT02181790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excimer laser
Description: twice weekly treatments with the excimer laser for a total of 8 weeks.
Study NCT03166462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation by Sleep Medicine Specialists
Description: Patients randomized to the intervention arm will be referred to the sleep medicine specialists for evaluation. All of their recommendations will be followed if indicated.
Study NCT02181790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acitretin
Description: 17.5mg/d
Study NCT01747343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Underwear/Differential Reinforcement
Description: Participants are going to be placed in underwear. Differential reinforcement will then be implemented.
Study NCT03005561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Play Back Sessions
Description: 100 participants that will be participating in two Play Back meetings. Playback define that improvisation as a theater facilitator asks the audience to share moments, feelings and stories of his daily life, and a group of actors improvise their stories in front of the stage as a kind of play-back. Unlike hobbies such as sports or singing, the method allows not only to unload the tensions but also communication and collaboration. It is very reminiscent of psychodrama, but unlike, is not considered a therapeutic tool.
Study NCT03813524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiovalve Transfemoral Mitral Valve
Description: The Cardiovalve Transfemoral Mitral Valve System is intended for use symptomatic patients with severe mitral regurgitation who are at elevated risk for surgical mitral valve repair or replacement and who are anatomically eligible for transfemoral mitral valve replacement with transseptal access to the left atrium.
Study NCT01263132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F0434
Description: F0434 will be administered orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose. The subject will continue with this dosage for one week and afterwards, the initial dosage will be increased from 3 capsules per day divided into 3 doses with the same time interval between doses, until visit 3 (week 2).
Study NCT01263132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin will be administered orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose. The subject will continue with this dosage for one week and afterwards, the initial dosage will be increased from 3 capsules per day divided into 3 doses with the same time interval between doses, until visit 3 (week 2)
Study NCT05768282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (30mg/day) for 28 days
Description: Oral prednisolone was started at a dose of 30 mg/day on the third day after RFA, and continued for 4 weeks.
Study NCT04241640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam 20 MG/ML
Description: Nefopam group nefopam 20 mg during surgery and follow by 80 mg in 24 hours postoperative
Study NCT04241640 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03474939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam Oral Tablet
Description: Midazolam Oral tablet
Study NCT03474939 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Glucose 1000mg tablet night before surgery and 60 minutes before surgery
Study NCT01246024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ERG
Description: scotopic and photopic ERG
Study NCT05072834 — intervention group
Intervention type: PROCEDURE
Intervention: Upper Gastrointestinal Endoscopy
Description: Procedure Upper gastro-intestinal endoscopic procedure involves collection of intestinal samples and it can be helpful in identifying the causes of malnutrition. Upon parental approval, the child along with two relatives will be provided transportation to Karachi, accommodation and the compensation for their time and expenses.~For this procedure the child will be admitted to the hospital a day before the procedure till one day after the procedure. This procedure takes 30 minutes, requires general anesthesia and involves insertion of a flexible tube with a small TV camera and a light on one end and an eyepiece on the other. The endoscope will allow the doctor to examine the inside of certain tube-like structures in the body. Some tissue samples for laboratory testing will be taken.
Study NCT03399331 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Manuka honey
Description: 5 for children or 10cc of honey for adults was ordered directly from a New Zealand company
Study NCT03399331 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: olive oil
Description: 5 cc of extra virgin olive oil for adults and 2 cc for children directly from a local distributor in south Lebanon will be given.
Study NCT03399331 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Control at our institution is 5cc sodium bicarbonate, 5cc rinsidin and 5cc of mycostatin 4 times daily for children. For adults it is Caphosol in the BMT unit and in the Basile inpatient unit it is the magic solution (without xylocaine).
Study NCT02704403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elafibranor
Study NCT02704403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01731756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leaf extract of A. indica
Description: Leaf extract of A. indica plus 6% salicylic acid will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks.
Study NCT04808336 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PRP injection.
Description: Group 1: thirty patients were injected in the facet joint capsule with a series of three ultrasound-guided PRP injections at four-week intervals,
Study NCT04808336 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fixation surgical procedure
Description: Group 2: thirty patients underwent surgery
Study NCT01194986 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [11C]AZ12807110
Description: Radioligand
Study NCT01194986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5213
Study NCT01731756 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Salicylic Acid (6%)
Description: Salicylic acid (6%) will be applied on palmer keratotic lesion once daily on bedtime for 12 weeks.
Study NCT01731756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salicylic Acid (6%)
Description: Salicylic acid (6%) will be applied on palmer keratotic lesion once daily on bedtime for 12 weeks.
Study NCT01731756 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Petroleum jelly
Description: Petroleum jelly will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks.
Study NCT01731756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Petroleum jelly
Description: Petroleum jelly will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks.